Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments

Evolving intensiveness of colorectal cancer (CRC) treatment, including chemotherapeutics and targeted agents associations, in adjuvant and metastatic CRC (MCRC) settings, increased overall survival (OS) with individual variability of toxicity. Pharmacogenomic guidelines recommended pre-treatment ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruera, Gemma, Ricevuto, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678498/
https://www.ncbi.nlm.nih.gov/pubmed/33235483
http://dx.doi.org/10.2147/PGPM.S253586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7678498/
https://www.ncbi.nlm.nih.gov/pubmed/33235483
http://dx.doi.org/10.2147/PGPM.S253586

Ejemplares similares